(19)
(11) EP 3 548 088 A1

(12)

(43) Date of publication:
09.10.2019 Bulletin 2019/41

(21) Application number: 17876335.5

(22) Date of filing: 22.11.2017
(51) International Patent Classification (IPC): 
A61K 47/55(2017.01)
A61P 35/04(2006.01)
 A61K 47/64(2017.01)
(86) International application number:
PCT/US2017/062976
(87) International publication number:
WO 2018/102212 (07.06.2018 Gazette 2018/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 01.12.2016 US 201662428655 P

(71) Applicant: Immunomedics, Inc.
Morris Plains, NJ 07950 (US)

(72) Inventors:
  • GOVINDAN, Serengulam V.
    Morris Plains, New Jersey 07950 (US)
  • GOLDENBERG, David M.
    Morris Plains, New Jersey 07950 (US)

(74) Representative: Bohmann, Armin K. 
Bohmann Anwaltssozietät Nymphenburger Straße 1
80335 München
80335 München (DE)

   


(54) THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)